Capital Group Investment Management PTE. LTD. Raises Stock Holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Capital Group Investment Management PTE. LTD. lifted its stake in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 30.2% during the fourth quarter, Holdings Channel reports. The fund owned 3,689 shares of the biotechnology company’s stock after purchasing an additional 856 shares during the quarter. Capital Group Investment Management PTE. LTD.’s holdings in Sarepta Therapeutics were worth $449,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Charles Schwab Investment Management Inc. boosted its stake in shares of Sarepta Therapeutics by 2.0% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 623,749 shares of the biotechnology company’s stock worth $75,842,000 after purchasing an additional 12,000 shares during the last quarter. Proficio Capital Partners LLC acquired a new stake in Sarepta Therapeutics during the fourth quarter worth approximately $3,829,000. Nordea Investment Management AB grew its stake in Sarepta Therapeutics by 19.1% in the 4th quarter. Nordea Investment Management AB now owns 67,546 shares of the biotechnology company’s stock worth $8,228,000 after acquiring an additional 10,815 shares during the period. Allspring Global Investments Holdings LLC raised its holdings in Sarepta Therapeutics by 16,717.7% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 85,434 shares of the biotechnology company’s stock valued at $10,602,000 after acquiring an additional 84,926 shares during the last quarter. Finally, Van ECK Associates Corp lifted its stake in shares of Sarepta Therapeutics by 24.4% during the 4th quarter. Van ECK Associates Corp now owns 84,834 shares of the biotechnology company’s stock worth $10,315,000 after purchasing an additional 16,658 shares during the period. Hedge funds and other institutional investors own 86.68% of the company’s stock.

Sarepta Therapeutics Stock Performance

Sarepta Therapeutics stock opened at $53.79 on Friday. The company has a debt-to-equity ratio of 0.93, a current ratio of 3.84 and a quick ratio of 3.03. The firm’s fifty day moving average price is $83.33 and its 200 day moving average price is $108.35. The company has a market capitalization of $5.22 billion, a price-to-earnings ratio of 43.03 and a beta of 0.93. Sarepta Therapeutics, Inc. has a 12-month low of $48.01 and a 12-month high of $173.25.

Analysts Set New Price Targets

SRPT has been the subject of a number of recent analyst reports. Royal Bank of Canada downgraded Sarepta Therapeutics from an “outperform” rating to a “sector perform” rating and lowered their price objective for the company from $161.00 to $87.00 in a research report on Monday, March 31st. HC Wainwright reaffirmed a “neutral” rating and set a $75.00 price objective on shares of Sarepta Therapeutics in a research note on Wednesday. Morgan Stanley decreased their target price on shares of Sarepta Therapeutics from $196.00 to $182.00 and set an “overweight” rating on the stock in a research report on Friday, April 11th. Wells Fargo & Company began coverage on shares of Sarepta Therapeutics in a research report on Friday, April 11th. They set an “overweight” rating and a $115.00 price target for the company. Finally, Needham & Company LLC decreased their price target on shares of Sarepta Therapeutics from $202.00 to $183.00 and set a “buy” rating on the stock in a report on Thursday, April 3rd. Six analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $161.83.

Insider Buying and Selling

In other Sarepta Therapeutics news, Director Claude Nicaise sold 2,491 shares of Sarepta Therapeutics stock in a transaction that occurred on Wednesday, March 12th. The stock was sold at an average price of $99.64, for a total transaction of $248,203.24. Following the sale, the director now directly owns 27,812 shares in the company, valued at $2,771,187.68. The trade was a 8.22 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 7.70% of the company’s stock.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.